Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Combined With Cetuximab in Recurrent/Metastatic HNSCC
NCT03082534Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Mar 2017
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and KL-140 in head and neck squamous cell carcinoma (HNSCC) (4 cohorts), sponsored by University of California, San Diego. Primary endpoint: Overall Response Rate at 6 months. Started Mar 2017; status: completed.
02
Drugs
pembrolizumabKL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03082534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082534.